What the study found
Olutasidenib, an IDH1 inhibitor, was generally well tolerated in patients with recurrent, locally advanced, or metastatic IDH1-mutated chondrosarcoma. The authors report disease control in conventional chondrosarcoma, a common subtype of this rare cartilage tumor.
Why the authors say this matters
The study suggests this is relevant because chondrosarcomas have limited treatment options, and IDH1/2 mutations are common in them. The authors conclude that the findings support olutasidenib as a tolerated option with disease-control activity in conventional chondrosarcoma.
What the researchers tested
The researchers carried out a phase 1b/2 trial in patients with locally advanced or metastatic IDH1-mutated chondrosarcoma. Patients received olutasidenib 150 mg twice daily, and the study measured objective response rate, adverse events, progression-free survival, and overall survival.
What worked and what didn't
Twenty-three patients were enrolled, including 16 with conventional chondrosarcoma. In 21 response-evaluable patients, 11 had stable disease, 8 had progressive disease, and 2 were not evaluable; in the conventional chondrosarcoma group, 10 had stable disease and 6 had progressive disease. Median progression-free survival was 2.0 months overall and 3.5 months in conventional chondrosarcoma, while median overall survival was 16.0 months overall and 19.0 months in conventional chondrosarcoma. No dose-limiting toxicities were reported.
What to keep in mind
The abstract notes an open-label design and a small sample size because conventional chondrosarcoma is rare. The summary does not describe a randomized comparison group, and it does not report objective tumor responses beyond stable or progressive disease.
Key points
- Olutasidenib was studied in recurrent, locally advanced, or metastatic IDH1-mutated chondrosarcoma.
- No dose-limiting toxicities were reported.
- Among 21 response-evaluable patients, 11 had stable disease and 8 had progressive disease.
- In conventional chondrosarcoma, 10 patients had stable disease and 6 had progressive disease.
- Median progression-free survival was 2.0 months overall and 3.5 months in conventional chondrosarcoma.
Disclosure
- Research title:
- Olutasidenib showed disease control in some chondrosarcoma patients
- Authors:
- Robin L. Jones, Roman Groisberg, Jean-Yves Blay, H. Colman, M. De La Fuente, Patricia Roxburgh, Mwe Mwe Chao, Hua Tian, Florence Duffaud, Rastislav Bahleda, Brian A. Van Tine
- Institutions:
- Aix-Marseille Université, Centre Léon Bérard, Huntsman Cancer Institute, Institut Gustave Roussy, Rigel (United States), Rigel (United States), Royal Marsden Hospital, Rutgers Cancer Institute, Rutgers, The State University of New Jersey, Sylvester Comprehensive Cancer Center, University of Glasgow, University of Miami, University of Utah, Washington University in St. Louis
- Publication date:
- 2026-01-29
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.